QQQ   437.73 (+0.57%)
AAPL   180.89 (-0.29%)
MSFT   407.71 (+0.00%)
META   488.92 (+1.01%)
GOOGL   137.02 (+0.47%)
AMZN   174.70 (+0.89%)
TSLA   200.68 (-0.67%)
NVDA   793.46 (+2.17%)
NIO   5.67 (+4.42%)
AMD   187.82 (+6.39%)
BABA   74.27 (-0.43%)
T   17.00 (+0.24%)
F   12.46 (+1.30%)
MU   89.55 (-0.18%)
CGC   3.32 (-1.19%)
GE   155.98 (+0.24%)
DIS   111.50 (+0.63%)
AMC   4.40 (-11.82%)
PFE   26.94 (-0.37%)
PYPL   60.78 (+0.88%)
XOM   104.69 (+0.35%)
QQQ   437.73 (+0.57%)
AAPL   180.89 (-0.29%)
MSFT   407.71 (+0.00%)
META   488.92 (+1.01%)
GOOGL   137.02 (+0.47%)
AMZN   174.70 (+0.89%)
TSLA   200.68 (-0.67%)
NVDA   793.46 (+2.17%)
NIO   5.67 (+4.42%)
AMD   187.82 (+6.39%)
BABA   74.27 (-0.43%)
T   17.00 (+0.24%)
F   12.46 (+1.30%)
MU   89.55 (-0.18%)
CGC   3.32 (-1.19%)
GE   155.98 (+0.24%)
DIS   111.50 (+0.63%)
AMC   4.40 (-11.82%)
PFE   26.94 (-0.37%)
PYPL   60.78 (+0.88%)
XOM   104.69 (+0.35%)
QQQ   437.73 (+0.57%)
AAPL   180.89 (-0.29%)
MSFT   407.71 (+0.00%)
META   488.92 (+1.01%)
GOOGL   137.02 (+0.47%)
AMZN   174.70 (+0.89%)
TSLA   200.68 (-0.67%)
NVDA   793.46 (+2.17%)
NIO   5.67 (+4.42%)
AMD   187.82 (+6.39%)
BABA   74.27 (-0.43%)
T   17.00 (+0.24%)
F   12.46 (+1.30%)
MU   89.55 (-0.18%)
CGC   3.32 (-1.19%)
GE   155.98 (+0.24%)
DIS   111.50 (+0.63%)
AMC   4.40 (-11.82%)
PFE   26.94 (-0.37%)
PYPL   60.78 (+0.88%)
XOM   104.69 (+0.35%)
QQQ   437.73 (+0.57%)
AAPL   180.89 (-0.29%)
MSFT   407.71 (+0.00%)
META   488.92 (+1.01%)
GOOGL   137.02 (+0.47%)
AMZN   174.70 (+0.89%)
TSLA   200.68 (-0.67%)
NVDA   793.46 (+2.17%)
NIO   5.67 (+4.42%)
AMD   187.82 (+6.39%)
BABA   74.27 (-0.43%)
T   17.00 (+0.24%)
F   12.46 (+1.30%)
MU   89.55 (-0.18%)
CGC   3.32 (-1.19%)
GE   155.98 (+0.24%)
DIS   111.50 (+0.63%)
AMC   4.40 (-11.82%)
PFE   26.94 (-0.37%)
PYPL   60.78 (+0.88%)
XOM   104.69 (+0.35%)
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

$1.41
+0.05 (+3.68%)
(As of 11:03 AM ET)
Today's Range
$1.39
$1.50
50-Day Range
$0.80
$1.36
52-Week Range
$0.45
$1.91
Volume
1.12 million shs
Average Volume
912,865 shs
Market Capitalization
$317.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Gossamer Bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
249.3% Upside
$4.75 Price Target
Short Interest
Bearish
6.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.98mentions of Gossamer Bio in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.27) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.20 out of 5 stars

Medical Sector

174th out of 958 stocks

Pharmaceutical Preparations Industry

72nd out of 450 stocks


GOSS stock logo

About Gossamer Bio Stock (NASDAQ:GOSS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Stock Price History

GOSS Stock News Headlines

Gossamer Bio Inc (GOSS)
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Gossamer Bio Inc.
5 Small-Cap Stocks with High Potential
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
Gossamer Bio Stock (NASDAQ:GOSS) Insider Trades
COO & CFO of Gossamer Bio Picks Up 76% More Stock
Recap: Gossamer Bio Q3 Earnings
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/29/2024
Next Earnings (Estimated)
3/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
178
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$10.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+249.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-229,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.13 per share

Miscellaneous

Free Float
203,995,000
Market Cap
$306.56 million
Optionable
Optionable
Beta
1.57
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Faheem Hasnain (Age 66)
    Co-Founder, CEO, President & Chairman
    Comp: $902.52k
  • Mr. Bryan GiraudoMr. Bryan Giraudo (Age 49)
    COO & CFO
    Comp: $690.59k
  • Dr. Richard Aranda M.D. (Age 64)
    Chief Medical Officer
    Comp: $625.24k
  • Mr. Christian Waage (Age 57)
    Executive Vice President of Technical Operations & Administration
    Comp: $583.16k
  • Mr. Jeff Boerneke
    General Counsel & Secretary
  • Ms. Deanna Weber
    Senior Vice President of Human Resources
  • Mr. Mario Orlando
    Senior Vice President of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 65)
    Executive Vice President of Regulatory Affairs
  • Mr. Matt Cravets
    Senior Vice President of Biometrics
  • Dr. Lisa Elizabeth Nolan Ph.D. (Age 62)
    MD & President of Gossamer Bio Ireland














GOSS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price target for 2024?

5 brokers have issued 12-month price objectives for Gossamer Bio's stock. Their GOSS share price targets range from $1.25 to $10.00. On average, they expect the company's share price to reach $4.75 in the next year. This suggests a possible upside of 249.3% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2024?

Gossamer Bio's stock was trading at $0.9125 at the start of the year. Since then, GOSS shares have increased by 49.0% and is now trading at $1.36.
View the best growth stocks for 2024 here
.

Are investors shorting Gossamer Bio?

Gossamer Bio saw a decline in short interest in February. As of February 15th, there was short interest totaling 15,300,000 shares, a decline of 8.5% from the January 31st total of 16,720,000 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is presently 11.1 days.
View Gossamer Bio's Short Interest
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) issued its earnings results on Monday, November, 8th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.02. During the same period last year, the company earned ($0.80) EPS.

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.16%), Octagon Capital Advisors LP (4.08%), Platinum Investment Management Ltd. (3.09%), Palo Alto Investors LP (2.64%), Madison Avenue Partners LP (2.24%) and Armistice Capital LLC (1.84%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOSS) was last updated on 2/29/2024 by MarketBeat.com Staff